Hoffmann-La Roche: Carcinoma, Transitional Cell trials

The registry lists 12 Carcinoma, Transitional Cell studies with Hoffmann-La Roche as lead sponsor. 0 are open to participants now and 4 have results posted.

Early Phase 1 1Phase 1 3Phase 2 2Phase 3 2No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)TerminatedNCT03869190Phase 1/2Results posted
• A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based TherapyTerminatedNCT03029832Phase 2Results posted
• Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial CarcinomaCompletedNCT02807636Phase 3Results posted
• A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical ResectionTerminatedNCT02450331Phase 3Results posted
• A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010CompletedNCT05867121Phase 1
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT05581004Phase 1
• A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical PracticeCompletedNCT03782207
• Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid TumorsTerminatedNCT03454243Early Phase 1
• A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)TerminatedNCT03399643
• A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in ArgentinaCompletedNCT03330886
• A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)CompletedNCT03232593
• An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyApproved for marketingNCT02589717